Soligenix Inc.
$ 1.08
-3.57%
11 Feb - close price
- Market Cap 11,296,500 USD
- Current Price $ 1.08
- High / Low $ 1.12 / 1.06
- Stock P/E N/A
- Book Value 0.77
- EPS -3.44
- Next Earning Report f
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.69 %
- ROE -1.65 %
- 52 Week High 6.23
- 52 Week Low 1.02
About
Soligenix, Inc., an advanced stage biopharmaceutical company, focuses on developing and marketing products to treat rare diseases in the United States. The company is headquartered in Princeton, New Jersey.
Analyst Target Price
$17.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-07 | 2025-08-14 | 2025-05-08 | 2025-03-13 | 2024-11-11 | 2024-08-09 | 2024-05-10 | 2024-03-15 | 2023-11-13 | 2023-08-21 | 2023-05-15 | 2023-03-31 |
| Reported EPS | -0.58 | -0.82 | -1.06 | -1.14 | -0.78 | -1.31 | -0.18 | -0.23 | -0.16 | -0.22 | -0.36 | -4.58 |
| Estimated EPS | -0.12 | -0.11 | -0.67 | -1.56 | -1.09 | -1.77 | -0.19 | -0.19 | -0.29 | -0.49 | -1.25 | -1.12 |
| Surprise | -0.46 | -0.71 | -0.39 | 0.42 | 0.31 | 0.46 | 0.01 | -0.04 | 0.13 | 0.27 | 0.89 | -3.46 |
| Surprise Percentage | -383.3333% | -645.4545% | -58.209% | 26.9231% | 28.4404% | 25.9887% | 5.2632% | -21.0526% | 44.8276% | 55.102% | 71.2% | -308.9286% |
Next Quarterly Earnings
| Feb 2026 | |
|---|---|
| Reported Date | f |
| Fiscal Date Ending | o |
| Estimated EPS | r |
| Currency | m |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SNGX
2026-02-11 17:27:38
Soligenix (NASDAQ: SNGX) is advancing its photodynamic therapy, HyBryte(TM) (SGX301), for the treatment of cutaneous T-cell lymphoma (CTCL) and other inflammatory skin diseases. The company recently achieved a safety milestone in its Phase 3 clinical trial for HyBryte, highlighting the therapy's precision and selective targeting of diseased tissue. Photodynamic therapy leverages photosensitizers, light, and oxygen to effectively treat cancer with minimal systemic toxicity.
2026-02-09 19:29:32
Soligenix (NASDAQ: SNGX) has released positive top-line results from its phase 2 clinical trial for SGX945, an investigational treatment for aphthous ulcers associated with Behcet's disease. SGX945 is an innate defense regulator designed to modulate the immune response, reducing inflammation while preserving the immune system's ability to fight infection. The trial reported SGX945 to be safe and well-tolerated, offering a notable step forward for patients with this underserved condition.
2026-02-03 21:29:44
Soligenix (NASDAQ: SNGX) is advancing new treatment options for Cutaneous T-cell lymphoma (CTCL), a rare and chronic cancer with limited treatment options. The company is developing HyBryte(TM) (SGX301 or synthetic hypericin), aiming to improve tolerability and long-term quality of life for patients. CTCL is a form of non-Hodgkin lymphoma that primarily affects the skin and can persist for years or decades with challenging symptoms.
2026-02-03 16:29:58
Soligenix (NASDAQ: SNGX) is making strides in developing HyBryte(TM) (SGX301) as a treatment for Cutaneous T-cell lymphoma (CTCL), a rare and chronic cancer with limited existing options. The company's approach aims to improve tolerability and long-term quality of life for patients. CTCL is a non-Hodgkin lymphoma that affects the skin, presenting significant challenges even decades after its classification.
2026-02-02 20:29:45
Soligenix (NASDAQ: SNGX) is actively advancing its pipeline of biotherapeutics and public health solutions to address the growing global burden of rare diseases. With over 300 million people affected worldwide and many conditions lacking treatment options, the company is focused on specialized biotherapeutics for orphan diseases. The World Health Organization's recognition of rare diseases as a global health priority underscores the urgency and importance of Soligenix's efforts in this field.
2026-02-02 18:58:09
Soligenix (NASDAQ: SNGX) is actively advancing its pipeline of biotherapeutics and public health solutions to address the increasing global prevalence and impact of rare diseases. With over 300 million people affected worldwide, Soligenix focuses on developing innovative therapies for orphan diseases and other serious conditions with limited treatment options. The company's efforts are aligned with the World Health Organization's recognition of rare diseases as a global health priority, emphasizing the collective need for effective treatments.
